...
CELG-RI—

Bristol-Myers Squibb Company Ce

HealthcareDrug Manufacturers - General
$0.10
$0.00(-10.86%)
52W$0.01
$0.27
FinancialsValuationvs LLY
Updated Mar 1, 12:00 AM
RSI52
RS Rating97/99
Beta-0.54
Volatility273%
F-Score4/9
Mkt Cap—
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Bristol-Myers Squibb Company Ce shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 80% provides fundamental context to the price action. Investors should exercise caution due to high volatility (273% annualized), which requires wider risk management.

Relative Strength
97
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
-0.54
vs S&P 500
LOW VOL
52W Position
32%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$0.10
50 SMA > 100 SMA$0.07
100 SMA > 150 SMA$0.05
150 SMA > 200 SMA$0.05

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$0.09+5.62%ABOVE
50 SMA$0.10-0.20%BELOW
100 SMA$0.07+49.62%ABOVE
150 SMA$0.05+80.59%ABOVE
200 SMA$0.05+103.54%ABOVE

Price Performance

1D-10.9%
1W+14.8%
1M+7.4%
3M+267.3%
6M+179.9%
YTD+35.9%
1Y+166.9%
3Y-7.9%
52-Week Trading Range32% from low
$0.10
52W Low$0.01
52W High$0.27

Technical Indicators

RSI (14)NEUTRAL
52.4
305070
VCP ScoreCOOL
5/10
Base depth: 255.0%

Risk Profile

Beta
-0.54
52W Vol
273%
ATR
$0.02
Max DD (1Y)
-64%

Volume Analysis

Today
—
50D Avg
99.3K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24-96%
$0.04
Q1'25+120%
$1.20
Q2'25-23%
$0.64
Q3'25+80%
$1.08
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+11.77%
5 Years:+13.06%
3 Years:+1.36%
TTM:+1.26%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+182.32%

Stock Price CAGR

10 Years:-4.50%
5 Years:-8.81%
3 Years:-7.89%
1 Year:+166.94%

Return on Equity

10Y Avg:10.1%
5Y Avg:1.0%
3Y Avg:2.1%
Last Year:32.5%

Key Metrics

Market Cap—
Gross Margin56.8%
Net Margin-18.5%
Piotroski F-Score4/9

More CELG-RI Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CELG-RI vs LLYLLYJNJAZNBMY

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 97 meansCELG-RI outperformed 97% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of -0.54 means 154% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is CELG-RI in an uptrend right now?

CELG-RI has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CELG-RI overbought or oversold?

CELG-RI's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.

Is CELG-RI outperforming the market?

CELG-RI has a Relative Strength (RS) Rating of 97 out of 99. Yes, CELG-RI is a market leader, outperforming 97% of all stocks over the past 12 months.

Where is CELG-RI in its 52-week range?

CELG-RI is trading at $0.10, which is 36% of its 52-week high ($0.27) and 32% above its 52-week low ($0.01).

How volatile is CELG-RI?

CELG-RI has a Beta of -0.54 and 52-week volatility of 273%. It's less volatile than the S&P 500 - generally more stable.